The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Cidara Therapeutics | Common Stock | 171757107 | 3,998 | 1,508,794 | SH | SOLE | 1,508,794 | 0 | 0 | ||
| CymaBay Therapeutics | Common Stock | 23257D103 | 7,324 | 551,477 | SH | SOLE | 551,477 | 0 | 0 | ||
| Dicerna Pharmaceuticals | Common Stock | 253031108 | 2,449 | 167,157 | SH | SOLE | 167,157 | 0 | 0 | ||
| ESSA Pharma | Common Stock | 29668H708 | 3,698 | 1,084,848 | SH | SOLE | 1,084,848 | 0 | 0 | ||
| FibroGen | Common Stock | 31572Q808 | 7,101 | 130,646 | SH | SOLE | 130,646 | 0 | 0 | ||
| Gossamer Bio | Common Stock | 38341P102 | 150,681 | 6,953,416 | SH | SOLE | 6,953,416 | 0 | 0 | ||
| Jounce Therapeutics | Common Stock | 481116101 | 3,286 | 529,965 | SH | SOLE | 529,965 | 0 | 0 | ||
| ObsEva | Common Stock | H5861P103 | 12,782 | 999,364 | SH | SOLE | 999,364 | 0 | 0 | ||
| Paratek Pharmaceuticals | Common Stock | 699374302 | 13,938 | 2,600,410 | SH | SOLE | 2,600,410 | 0 | 0 | ||
| Pieris Pharmaceuticals | Common Stock | 720795103 | 2,607 | 778,230 | SH | SOLE | 778,230 | 0 | 0 | ||
| Replimune | Common Stock | 76029N106 | 77,425 | 5,103,455 | SH | SOLE | 5,103,455 | 0 | 0 | ||
| Sienna Biopharmaceuticals | Common Stock | 82622H108 | 1,760 | 758,610 | SH | SOLE | 758,610 | 0 | 0 | ||
| Translate Bio | Common Stock | 89374L104 | 24,839 | 2,437,603 | SH | SOLE | 2,437,603 | 0 | 0 | ||